Table 1 Baseline characteristics of study participants
Characteristic | 10 mg kg−1 (N = 110) n (%) | 40 mg kg−1 (N = 110) n (%) | Placebo (N = 110) n (%) | |
|---|---|---|---|---|
Age (years) | Mean (s.d.) | 33.8 (9.3) | 34.4 (9.7) | 34.1 (9.7) |
Median | 34 | 35 | 35 | |
Minimum, maximum | 18, 54 | 18, 53 | 18, 53 | |
Sex | Male | 59 (53.6) | 63 (57.3) | 66 (60) |
Female | 51 (46.4) | 47 (42.7) | 44 (40) | |
Ethnicity | Bambara | 107 (97.3) | 103 (93.6) | 107 (97.3) |
Peuth | 1 (0.9) | 5 (4.5) | 0 | |
Sarakole | 2 (1.8) | 2 (1.8) | 3 (2.7) | |
Weight (kg) | Mean (s.d.) | 64.0 (9.9) | 62.3 (11.4) | 63.8 (11.4) |
Median | 63.5 | 61.5 | 63 | |
Minimum, maximum | 44, 95 | 43, 101 | 46, 114 | |
Site | Kalifabougou | 67 (60.9) | 67 (60.9) | 66 (60) |
Torodo | 43 (39.1) | 43 (39.1) | 44 (40) | |
Plasmodium detected on TBS at enrollment | Any species | 15 (13.6) | 9 (8.2) | 8 (7.3) |
P. falciparum | 14 (12.7) | 8 (7.3) | 8 (7.3) | |
Plasmodium malariae | 0 | 1 (0.9) | 0 | |
Plasmodium ovale | 1 (0.9) | 0 | 0 | |
Interval between administration of AL and CIS43LS | Mean (s.d.) | 9.1 (1.7) | 9.1 (1.6) | 9.2 (1.7) |
Median | 9 | 9 | 9 | |
Minimum, maximum | 7, 15 | 7, 14 | 7, 14 | |
Hemoglobin genotype | AA | 98 (89.1) | 93 (84.5) | 92 (83.6) |
AS | 7 (6.4) | 7 (6.4) | 10 (9.1) | |
AC | 3 (2.7) | 9 (8.2) | 8 (7.3) | |
CC | 0 | 1 (0.9) | 0 | |
SC | 2 (1.8) | 0 | 0 |
